Steven Cohen Biotechnology

Point72 Asset Management, L.P.

$44.6 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
AKRO Akero Therapeutics, Inc.	$2.5B	$145 Million 0.32% of portfolio	2,710,929	Q2 2025 Added 433.29%
IDYA Ideaya Biosciences, Inc.	$1.47B	$106 Million 0.24% of portfolio	5,028,279	Q2 2025 Added 3,488.42%
IMVT Immunovant, Inc.	$3.55B	$91.8 Million 0.21% of portfolio	3,336,250	Q2 2025 Added 316.03%
REGN Regeneron Pharmaceuticals, Inc.	$62.1B	$75.1 Million 0.17% of portfolio	143,108	Q2 2025 New
ACAD Acadia Pharmaceuticals Inc	$3.39B	$68.4 Million 0.15% of portfolio	3,172,511	Q2 2025 Reduced 31.74%
INCY Incyte Corp	$19.4B	$67.1 Million 0.15% of portfolio	985,083	Q2 2025 Added 188.02%
ALNY Alnylam Pharmaceuticals, Inc.	$58.3B	$65.7 Million 0.15% of portfolio	201,396	Q2 2025 Reduced 33.01%
CRNX Crinetics Pharmaceuticals, Inc.	$2.3B	$57.5 Million 0.13% of portfolio	1,998,161	Q2 2025 Added 156.7%
CLDX Celldex Therapeutics, Inc.	$1.29B	$57 Million 0.13% of portfolio	2,801,721	Q2 2025 Added 6.89%
JANX Janux Therapeutics, Inc.	$1.12B	$49.5 Million 0.11% of portfolio	2,143,900	Q2 2025 Added 469.18%
INSM Insmed Inc	$22.7B	$49.4 Million 0.11% of portfolio	490,667	Q2 2025 New
RCUS Arcus Biosciences, Inc.	$1.26B	$48.6 Million 0.11% of portfolio	5,966,664	Q2 2025 Added 108.11%
RLAY Relay Therapeutics, Inc.	$846M	$46.5 Million 0.1% of portfolio	13,445,704	Q2 2025 Added 24.19%
IMNM Immunome Inc.	$203M	$43.6 Million 0.1% of portfolio	4,685,803	Q2 2025 Added 7.46%
NRIX Nurix Therapeutics, Inc.	$490M	$42.2 Million 0.09% of portfolio	3,703,594	Q2 2025 Added 1,595.37%
TECH Bio Techne Corp	$2.49B	$40.5 Million 0.09% of portfolio	787,624	Q2 2025 Added 58.27%
AXSM Axsome Therapeutics, Inc.	$5.64B	$36.6 Million 0.08% of portfolio	350,973	Q2 2025 Added 178.12%
COGT Cogent Biosciences, Inc.	$1.09B	$35.3 Million 0.08% of portfolio	4,911,924	Q2 2025 Reduced 7.24%
CNTA Centessa Pharmaceuticals PLC	$2.15B	$34.1 Million 0.08% of portfolio	2,591,596	Q2 2025 Added 13.35%
MDGL Madrigal Pharmaceuticals, Inc.	$7.52B	$33.6 Million 0.08% of portfolio	110,877	Q2 2025 Added 68.35%
ROIV Roivant Sciences Ltd.	$12.5B	$33.3 Million 0.07% of portfolio	2,951,132	Q2 2025 Added 380.39%
DNLI Denali Therapeutics Inc.	$2.31B	$31 Million 0.07% of portfolio	2,213,947	Q2 2025 New
AMLX Amylyx Pharmaceuticals, Inc.	$895M	$29.1 Million 0.07% of portfolio	4,536,266	Q2 2025 Added 394.7%
ORIC Oric Pharmaceuticals, Inc.	$501M	$28.9 Million 0.06% of portfolio	2,850,641	Q2 2025 New
CRVS Corvus Pharmaceuticals, Inc.	$335M	$28.2 Million 0.06% of portfolio	7,042,373	Q2 2025 Added 152.63%
TGTX Tg Therapeutics, Inc.	$5.1B	$25.8 Million 0.06% of portfolio	717,510	Q2 2025 New
IMCR Immunocore Holdings PLC	$1.49B	$25.7 Million 0.06% of portfolio	820,425	Q2 2025 Added 30.58%
ETNB 89bio, Inc.	$688M	$22.3 Million 0.05% of portfolio	2,274,151	Q2 2025 New
ARQT Arcutis Biotherapeutics, Inc.	$1.26B	$20.8 Million 0.05% of portfolio	1,485,425	Q2 2025 Added 78.86%
ADCT Adc Therapeutics Sa	$333M	$20.8 Million 0.05% of portfolio	7,763,658	Q2 2025 New
SNDX Syndax Pharmaceuticals Inc	$881M	$19.9 Million 0.04% of portfolio	2,127,467	Q2 2025 Reduced 46.93%
FOLD Amicus Therapeutics, Inc.	$2.37B	$18.8 Million 0.04% of portfolio	3,279,047	Q2 2025 Added 9.85%
RARE Ultragenyx Pharmaceutical Inc.	$2.41B	$18.8 Million 0.04% of portfolio	515,968	Q2 2025 Reduced 47.14%
CTMX Cytom X Therapeutics, Inc.	$245M	$18.4 Million 0.04% of portfolio	8,084,623	Q2 2025 Added 205.08%
OCUL Ocular Therapeutix, Inc	$901M	$17.7 Million 0.04% of portfolio	1,904,214	Q2 2025 Reduced 1.96%
TSHA Taysha Gene Therapies, Inc.	$251M	$16.9 Million 0.04% of portfolio	7,317,614	Q2 2025 Added 60.13%
ADPT Adaptive Biotechnologies Corp	$2.55B	$16 Million 0.04% of portfolio	1,373,923	Q2 2025 New
GERN Geron Corp	$480M	$13.5 Million 0.03% of portfolio	9,606,217	Q2 2025 Added 34.79%
MIRM Mirum Pharmaceuticals, Inc.	$2.68B	$13.2 Million 0.03% of portfolio	258,866	Q2 2025 Added 11.53%
VTYX Ventyx Biosciences, Inc.	$210M	$12.6 Million 0.03% of portfolio	5,895,069	Q2 2025 Added 39.21%
BCYC Bicycle Therapeutics PLC	$242M	$12.3 Million 0.03% of portfolio	1,772,600	Q2 2025 Reduced 51.99%
IONS Ionis Pharmaceuticals Inc	$10.4B	$11.6 Million 0.03% of portfolio	292,647	Q2 2025 Added 1.9%
VRNA Verona Pharma PLC	$6.52B	$11.2 Million 0.03% of portfolio	118,578	Q2 2025 Added 25.72%
GMAB Genmab A/S	$19.8B	$11.1 Million 0.02% of portfolio	538,500	Q2 2025 Reduced 41.71%
RYTM Rhythm Pharmaceuticals, Inc.	$5.97B	$10.8 Million 0.02% of portfolio	170,832	Q2 2025 Added 167.59%
GLPG Galapagos Nv	$2.26B	$9.56 Million 0.02% of portfolio	341,500	Q2 2025 New
TRVI Trevi Therapeutics, Inc.	$618M	$9.46 Million 0.02% of portfolio	1,728,676	Q2 2025 Reduced 27.0%
MRUS Merus N.V.	$4.33B	$8.98 Million 0.02% of portfolio	170,777	Q2 2025 New
ZLAB Zai Lab LTD	$2.81B	$8.83 Million 0.02% of portfolio	252,400	Q2 2025 Added 186.27%
MLTX Moon Lake Immunotherapeutics	$338M	$8.81 Million 0.02% of portfolio	186,568	Q2 2025 New

Shares Options

Steven Cohen

Steven Cohen is the founder and CEO of Point72 Asset Management, a successful investment firm that uses technology and data-driven approaches to investing. Cohen is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track Steven Cohen's portfolio

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account